Navigation Links
Largest ever analysis of DES data demonstrates safety, efficacy in on-and-off-label use
Date:3/27/2008

CHICAGO, IL MARCH 27, 2008 The Cardiovascular Research Foundation (CRF) will present results of the largest meta-analysis to date comparing mortality rates for drug-eluting stents (DES) versus bare metal stents (BMS) at the Drug-Eluting Stent Revolution VII meeting tomorrow evening in Chicago.

The analysiswhich includes approximately 180,000 patients from 52 studieswas performed by a team of researchers led by Ajay J. Kirtane, MD, Assistant Professor of Clinical Medicine and an interventional cardiologist at NewYork-Presbyterian Hospital/Columbia University Medical Center, and Gregg W. Stone, MD, Chairman of CRF and Professor of Medicine at Columbia University Medical Center and Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital.

Drs. Kirtane and Stone conducted two parallel meta-analyses examining DES vs. BMS use in both randomized, controlled trials and in observational registry analyses. The overall analysis represents the largest systematic overview of real-world (comprising both on-label and off-label) DES use to date and incorporates an updated overview of both the published literature as well as the most recent data from several unpublished studies presented in the last year.

The findings from these parallel studies are striking, said Dr. Stone.

The meta-analysis of 22 randomized trials included more than 9000 patients with recent follow-up from previously published trials. According to the results, DES resulted in small non-significant reductions in death and MI, with a greater than 50% decrease in subsequent TVR procedures, said Dr. Stone, adding that these findings are consistent with both on-label and off-label use of DES.

And in the 30-study registry meta-analysis (involving more than 170,000 real-world patients), DES resulted in significant 20% and 11% reductions in death and MI, respectively, with a similar reduction in TVR (47%) as in the randomized trials, even after adjustment for confounding variables, said Dr. Stone. These data are reassuring that DES are safe and effective for a wide-range of patients that are able to take dual antiplatelet therapy for at least one year.

The findings were consistent and robust across a variety of study designs and even in trials incorporating longer-term follow-up; trials that were included were required to follow patients for at least one year.

Dr. Kirtane remarked that these findings should help to reassure patients and physicians about the safety of DES in off-label use.

Even with the stated limitations of registry data, the bottom line from both randomized trials and observational analyses is consistent: we can reduce the need for repeat procedures and we clearly are not harming patients with DES, he added.


'/>"/>

Contact: Irma Damhuis
idamhuis@crf.org
212-851-9187
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. An invitation to Europes largest forum on breast cancer
2. Spartan Stores Becomes Largest U.S. Supermarket Chain to Receive NSF Shop Fresh(TM) Certification
3. CVS, Americas Largest Pharmacy Chain, Pays Nearly $37 Million to Settle Federal and State Generic Drug Switching Charges
4. Grassini & Wrinkle Law Firm Are Awarded Largest PI Verdict in Ventura County History
5. Medco Breaks Ground For Worlds Largest Automated Pharmacy
6. Cardiac Science Delivers Largest Order of Electrocardiograph Systems in Company History
7. AMSA Annual Convention: Largest Gathering of Medical Students Celebrates 58 Years of Student Activism
8. McGraw-Hill Professional Enters Partnership with American College of Physicians, the Worlds Largest Internal Medicine Organization
9. Netsmart Technologies Acquires Largest Provider of Software for Private Practice Mental Health Providers and Therapists
10. Crdentia Selected by Leading Staffing Vendor to Provide Health Care Staffing Services to One of the Largest Hospital Chains in the U.S.
11. $30.3 Million Jury Verdict Believed to Be New Jerseys Largest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... , ... Hammer Strength, the world’s leading performance strength training brand, and the ... Rockets the NBSCA Strength & Conditioning Coach of the Year. , In its ... to select the coach who embodies the highest level of excellence and outstanding service ...
(Date:6/27/2017)... CA (PRWEB) , ... June 27, 2017 , ... East ... crooked bites can indicate about early life experiences. What happens to a woman during ... that stresses after birth can also take a toll on a baby’s long-term health. ...
(Date:6/26/2017)... ... ... Center is now offering various types of dental implants to restore lost teeth. Dental ... teeth, such as crowns, bridges, or dentures. An implant is placed directly into the jawbone ... the tooth. , Several types of dental implants are available, including: , ...
(Date:6/26/2017)... MD. (PRWEB) , ... June 26, 2017 , ... ... crop, according to a recent review of government data released by the United ... improvement in management practices, Maryland’s soybean farmers have increased their productivity on less ...
(Date:6/26/2017)... ... June 26, 2017 , ... If the ... seeing lots of red these days. According to recent estimates, 75 – 80% ... medical coding errors(1). Some studies point to Electronic Health Records (EHR) with automated ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... 2017 The Bio Supply Management Alliance (BSMA) ... Fremont and the Biomedical Manufacturing Network to ... California by providing a platform ... fostering workforce development. The primary focus of this alliance ... as well as small and mid-sized biomedical companies. ...
(Date:6/12/2017)... SEATTLE , June 12, 2017 Kineta, Inc., ... today announced Kineta Vice President of R&D and ... at the Pandemic Preparedness for the Northwest and Beyond ... be held on June 14, 2017 from 8:30-10:30 AM PDT ... Dr. Bedard will be joined ...
(Date:6/9/2017)... AirXpanders, Inc. (ASX: AXP) (AirXpanders or Company), ... sale and distribution of the AeroForm® Tissue Expander System, ... commercial roll-out in the United States ... hundred (100) medical institutions and health systems, located throughout ... alternative for women who choose reconstructive surgery following a ...
Breaking Medicine Technology: